The ExoGAN generative AI framework enables extracellular vesicle-based immunotherapy

Area of Science:

• Immunology
• Artificial Intelligence
• Biotechnology

Background:

• Neoantigens (tumor antigenic peptides presented by MHC-I) are crucial for CD8+ T cell activation in cancer immunotherapy.
• Current immunotherapies face challenges due to patient-specific tumor heterogeneity and unpredictable T Cell Receptor (TCR) binding properties.
• Developing novel neoantigens with predictable TCR recognition is essential for effective cancer treatment.

Purpose of the Study:

• To introduce ExoGAN, a generative AI framework designed to guide the creation of novel tumor antigenic peptides.
• To engineer extracellular vesicles (EVs) decorated with ExoGAN-designed peptides for enhanced T cell activation and anti-tumor immunity.
• To improve the predictability and efficacy of cancer immunotherapy through AI-driven neoantigen design.

Main Methods:

• Developed ExoGAN, a generative adversarial network (GAN) integrating HLA physiochemistry and sequence data for peptide design.
• Trained ExoGAN on the largest IEDB dataset of HLA peptides to design HLA-A*02:01-targeting peptides.
• Engineered extracellular vesicles (EVs) to present ExoGAN-designed peptides in MHC complex proteins for targeted delivery and T cell activation.

Main Results:

• ExoGAN successfully designed novel human neoantigens with improved TCR recognition and T cell activation potential.
• EVs decorated with ExoGAN-designed peptides demonstrated consistent antigenic presentation to T cell TCRs.
• Computational and experimental validation confirmed programmable EV agents for effective anti-tumor immunity activation.

Conclusions:

• The ExoGAN framework enables the design of neoantigens with enhanced TCR recognition and T cell activation capabilities.
• EV-based delivery of ExoGAN-designed peptides offers a programmable platform for precision cancer immunotherapy.
• This approach advances mechanistic understanding of neoantigen functionality and accelerates the development of novel immunotherapy agents.